Press releases
US-specific press releases are available here. Please visit our global website for access to global press releases dating back to 2009.
-
Vir Biotechnology and GSK provide update on NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
The independent DSMB has recommended that the VIR-7831 arm of the trial be closed to enrolment while the data mature.
Read more -
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021
16 sponsored abstracts from our diverse portfolio of innovative pipeline and licensed HIV treatment and prevention options will be presented
Read more -
GSK announces results evaluating its investigational monoclonal antibody, otilimab, for the treatment of hospitalised adult patients with COVID-19
GSK today announce results from the phase 2 proof of concept OSCAR study with otilimab, an investigational anti-GM-CSF monoclonal antibody.
Read more -
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months
ViiV Healthcare with Pfizer Inc. and Shionogi Limited as shareholders, announced today the submission of a sNDA to the US FDA
Read more -
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults.
Read more -
GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
Companies to combine expertise in immunology and infectious diseases to accelerate development of promising new therapeutics for influenza.
Read more -
GSK announces gender and diversity aspirational targets to increase representation at senior levels
Aspirational targets to increase ethnically diverse senior leadership in the US and UK.
Read more -
GSK announces over $1M for local nonprofits to increase equity in STEM education and careers; Grants include funding for online science during pandemic
Our 10-year commitment to increase the number of women and Black and Latinx Philadelphia students entering careers in STEM
Read more -
GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER
Strong growth of new and specialty products; on track to deliver two exciting new companies
Read more -
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
Read more -
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases.
Read more -
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.
Read more -
GSK ranks 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases
Ranking reflects GSK leadership through access to its medicines and vaccines for people around the world.
Read more -
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
ViiV Healthcare announces FDA approval of Cabenuva, the first & only complete long-acting regimen for HIV treatment
Read more -
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
Read more -
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment.
Read more -
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
Read more -
FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Approval builds on nearly 10 years of experience in lupus
Read more -
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
Read more -
FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
If approved, Nucala would be the only treatment approved in the US for use in four eosinophil-driven diseases.
Read more
Find out more about us
-
About us
Uniting science, technology and talent to get ahead of disease together
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research and development
Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients.
